Skip to main content
SpringerLink
Log in

Thrombotic Microangiopathy Not Associated with the Classic/Idiopathic TTP-HUS

  • Chapter
  • First Online:
Core Concepts in Parenchymal Kidney Disease

  • 1296 Accesses

Abstract

Thrombotic microangiopathy (TMA) is characterized by the formation of platelet thrombi and vascular wall injury in the microcirculation associated with hallmark clinical features of acute thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and visceral organ injury, especially involving the kidneys and brain. Of all TMA cases, a third of them are due to the classic TTP-HUS; the remaining two-thirds are nonclassic and considered as secondary TMA that occurs in a variety of clinical settings including in microangiopathic antiphospholipid syndrome (MAPS), systemic lupus erythematosus (SLE) and other connective tissue diseases, a wide range of systemic infections, pregnancy, drug ingestion, disseminated malignancy, solid organ transplantation, bone marrow and hematopoietic stem cell transplantations, and, rarely, with severe pancreatitis and surgery. This chapter focuses on entities of secondary TMA and reviews their pathogenesis, clinicopathological presentation, diagnosis, prognosis, and treatment strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.

    Article  PubMed  CAS  Google Scholar 

  2. Asherson RA, Pierangeli S, Cervera R. Microangiopathic antiphospholipid-associated syndromes revisited new concepts relating to antiphospholipid antibodies and syndromes. J Rheumatol. 2007;34:1793–5.

    PubMed  Google Scholar 

  3. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005;106:2340–6.

    Article  PubMed  CAS  Google Scholar 

  4. Ramesh S, Morrell CN, Tarango C, et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via beta2GPI and apoER2. J Clin Invest. 2011;121:120–31.

    Article  PubMed  CAS  Google Scholar 

  5. Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood. 2005;105:1964–9.

    Article  PubMed  CAS  Google Scholar 

  6. Pennings MT, Derksen RH, van Lummel M, et al. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ib alpha and apolipoprotein E receptor 2′. J Thromb Haemost. 2007;5:369–77.

    Article  PubMed  CAS  Google Scholar 

  7. Satta N, Dunoyer-Geindre S, Reber G, et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood. 2007;109:1507–14.

    Article  PubMed  CAS  Google Scholar 

  8. Shi W, Chong BH, Chesterman CN. Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood. 1993;81:1255–62.

    PubMed  CAS  Google Scholar 

  9. Zhou H, Wolberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood. 2004;104:2353–8.

    Article  PubMed  CAS  Google Scholar 

  10. Pierangeli SS, Chen PP, Raschi E, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost. 2008;34:236–50.

    Article  PubMed  CAS  Google Scholar 

  11. Lambrianides A, Carroll CJ, Pierangeli SS, et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol. 2010;184:6622–8.

    Article  PubMed  CAS  Google Scholar 

  12. Oku K, Amengual O, Atsumi T. Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome. Eur J Clin Invest. 2012;42(10):1126–35.

    Article  PubMed  CAS  Google Scholar 

  13. Bohgaki M, Atsumi T, Yamashita Y, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol. 2004;16:1633–41.

    Article  PubMed  CAS  Google Scholar 

  14. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 2005;52:2120–4.

    Article  PubMed  CAS  Google Scholar 

  15. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10:1222–6.

    Article  PubMed  CAS  Google Scholar 

  16. Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol. 2007;196:167.e161–165.

    Article  CAS  Google Scholar 

  17. Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med. 1995;182:1807–14.

    Article  PubMed  CAS  Google Scholar 

  18. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med. 1997;185:1619–27.

    Article  PubMed  CAS  Google Scholar 

  19. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498–509.

    Article  PubMed  CAS  Google Scholar 

  20. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006;203:2165–75.

    Article  PubMed  CAS  Google Scholar 

  21. Cervera R. Catastrophic antiphospholipid syndrome (CAPS): update from the ‘CAPS Registry’. Lupus. 2010;19:412–8.

    Article  PubMed  CAS  Google Scholar 

  22. Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine. 2008;87:345–64.

    Article  PubMed  Google Scholar 

  23. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant. 2011;11:2523–7.

    Article  PubMed  CAS  Google Scholar 

  24. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010;362:1744–5.

    Article  PubMed  CAS  Google Scholar 

  25. Matsuyama T, Kuwana M, Matsumoto M, Isonishi A, Inokuma S, Fujimura Y. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost. 2009;102:371–8.

    PubMed  CAS  Google Scholar 

  26. Vaidya S, Abul-ezz S, Lipsmeyer E. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Scand J Rheumatol. 2001;30:308–10.

    Article  PubMed  CAS  Google Scholar 

  27. Kwok SK, Ju JH, Cho CS, Kim HY, Park SH. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study. Lupus. 2009;18:16–21.

    Article  PubMed  CAS  Google Scholar 

  28. Chen MH, Chen WS, Mu-Hsin Chang P, Lee HT, Lin HY, Huang DF. Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology (Oxford). 2011;50:768–75.

    Article  Google Scholar 

  29. Musio F, Bohen EM, Yuan CM, Welch PG. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum. 1998;28:1–19.

    Article  PubMed  CAS  Google Scholar 

  30. Letchumanan P, Ng HJ, Lee LH, Thumboo J. A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology (Oxford). 2009;48:399–403.

    Article  Google Scholar 

  31. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325:398–403.

    Article  PubMed  CAS  Google Scholar 

  32. Limal N, Cacoub P, Sene D, Guichard I, Piette JC. Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Lupus. 2008;17:69–71.

    Article  PubMed  CAS  Google Scholar 

  33. Kamiya K, Kurasawa K, Arai S, et al. Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus. Mod Rheumatol. 2010;20:81–5.

    Article  PubMed  Google Scholar 

  34. Walker JG, Ahern MJ, Smith MD, et al. Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Intern Med J. 2003;33:216–20.

    Article  PubMed  CAS  Google Scholar 

  35. Steen VD, Syzd A, Johnson JP, Greenberg A, Medsger Jr TA. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol. 2005;32:649–55.

    PubMed  Google Scholar 

  36. Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007;100:485–94.

    Article  PubMed  CAS  Google Scholar 

  37. Naniwa T, Banno S, Sugiura Y, Yokota K, Maeda S, Hayami Y, Takahashi N, Ueda R, Matsumoto Y. Pulmonary-renal syndrome in systemic sclerosis: a report of three cases and review of the literature. Mod Rheumatol. 2007;17(1): 37–44.

    Google Scholar 

  38. Teixeira L, Mouthon L, Mahr A, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis. 2008;67:110–6.

    Article  PubMed  CAS  Google Scholar 

  39. Guillevin L, Berezne A, Seror R, et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford). 2012;51:460–7.

    Article  CAS  Google Scholar 

  40. Steen VD, Costantino JP, Shapiro AP, Medsger Jr TA. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990;113:352–7.

    Article  PubMed  CAS  Google Scholar 

  41. Kitiyakara C, Guzman NJ. Malignant hypertension and hypertensive emergencies. J Am Soc Nephrol. 1998;9:133–42.

    PubMed  CAS  Google Scholar 

  42. van den Born BJH, Honnebier UPF, Koopmans RP, van Montfrans GA. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension 2005;45:246–51.

    Google Scholar 

  43. van den Born BJH, van der Hoeven NV, Groot E, Lenting PJ, Meijers JCM, Levi M, van Montfrans GA. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension. 2008;51:862–6

    Google Scholar 

  44. Khanna A, McCullough PA. Malignant hypertension presenting as hemolysis, thrombocytopenia, and renal failure. Rev Cardiovasc Med. 2003;4:255–9.

    PubMed  Google Scholar 

  45. Rivera A, Montoya E, Varon J. Intravenous clevidipine for management of hypertension. Integr Blood Press Control. 2010;3:105–11.

    PubMed  CAS  Google Scholar 

  46. Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies. Cochrane Database Syst Rev. 2008:CD003653.

    Google Scholar 

  47. Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356:411–7.

    Article  PubMed  CAS  Google Scholar 

  48. Scarpelli PT, Gallo M, De Cesaris F, et al. Continuing follow-up of malignant hypertension. J Nephrol. 2002;15:431–7.

    PubMed  Google Scholar 

  49. Miner PE, Nutt RL, Thomas ME. Thrombotic thrombocytopenic purpura occurring in pregnancy. Am J Obstet Gynecol. 1955;70:611–7.

    PubMed  CAS  Google Scholar 

  50. Weiner CP. Thrombotic microangiopathy in pregnancy and the postpartum period. Semin Hematol. 1987;24:119–29.

    PubMed  CAS  Google Scholar 

  51. Dashe JS, Ramin SM, Cunningham FG. The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy. Obstet Gynecol. 1998;91:662–8.

    Article  PubMed  CAS  Google Scholar 

  52. Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost. 1984;52:176–82.

    PubMed  CAS  Google Scholar 

  53. de Moerloose P, Mermillod N, Amiral J, Reber G. Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1. Thromb Haemost. 1998;79:554–6.

    PubMed  Google Scholar 

  54. Valera MC, Parant O, Vayssiere C, Arnal JF, Payrastre B. Physiologic and pathologic changes of platelets in pregnancy. Platelets. 2010;21:587–95.

    Article  PubMed  CAS  Google Scholar 

  55. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98:2730–5.

    Article  PubMed  CAS  Google Scholar 

  56. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340:9–13.

    Article  PubMed  CAS  Google Scholar 

  57. Hayward CP, Sutton DM, Carter Jr WH, et al. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Arch Intern Med. 1994;154:982–7.

    Article  PubMed  CAS  Google Scholar 

  58. Egerman RS, Witlin AG, Friedman SA, Sibai BM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in pregnancy: review of 11 cases. Am J Obstet Gynecol. 1996;175:950–6.

    Article  PubMed  CAS  Google Scholar 

  59. Shamseddine A, Chehal A, Usta I, Salem Z, El-Saghir N, Taher A. Thrombotic thrombocytopenic purpura and pregnancy: report of four cases and literature review. J Clin Apher. 2004;19:5–10.

    Article  PubMed  Google Scholar 

  60. Royer DJ, George JN, Terrell DR. Thrombocytopenia as an adverse effect of complementary and alternative medicines, herbal remedies, nutritional supplements, foods, and beverages. Eur J Haematol. 2010;84:421–9.

    Article  PubMed  Google Scholar 

  61. Stroncek DF, Vercellotti GM, Hammerschmidt DE, Christie DJ, Shankar RA, Jacob HS. Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. Blood. 1992;80:241–8.

    PubMed  CAS  Google Scholar 

  62. Gottschall JL, Elliot W, Lianos E, McFarland JG, Wolfmeyer K, Aster RH. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity. Blood. 1991;77:306–10.

    PubMed  CAS  Google Scholar 

  63. Maguire RB, Stroncek DF, Campbell AC. Recurrent pancytopenia, coagulopathy, and renal failure associated with multiple quinine-dependent antibodies. Ann Intern Med. 1993;119:215–7.

    Article  PubMed  CAS  Google Scholar 

  64. Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol. 1989;7:781–9.

    PubMed  CAS  Google Scholar 

  65. Izzedine H, Isnard-Bagnis C, Launay-Vacher V, et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant. 2006;21:3038–45.

    Article  PubMed  CAS  Google Scholar 

  66. De Smet D, Jochmans K, Neyns B. Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine. Ann Hematol. 2008;87:495–6.

    Article  PubMed  Google Scholar 

  67. Carson JM, Newman ED, Farber JL, Filippone EJ. Tacrolimus-induced thrombotic microangiopathy: natural history of a severe, acute vasculopathy. Clin Nephrol. 2012;77:79–84.

    PubMed  CAS  Google Scholar 

  68. Said T, Al-Otaibi T, Al-Wahaib S, et al. Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome: single-center experience. Transplant Proc. 2010;42:814–6.

    Article  PubMed  CAS  Google Scholar 

  69. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med. 1998;128:541–4.

    Article  PubMed  CAS  Google Scholar 

  70. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342:1773–7.

    Article  PubMed  CAS  Google Scholar 

  71. Leach JW, Pham T, Diamandidis D, George JN. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): a case report. Am J Hematol. 1999;61:268–70.

    Article  PubMed  CAS  Google Scholar 

  72. Dahabreh I, Tsoutsos G, Tseligas D, Janinis D. Hemolytic uremic syndrome following the infusion of oxaliplatin: case report. BMC Clin Pharmacol. 2006;6:5.

    Article  PubMed  Google Scholar 

  73. Martin MG, Whitlatch NL, Shah B, Arepally GM. Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah’s Witness. Am J Hematol. 2007;82:679–81.

    Article  PubMed  Google Scholar 

  74. Bollee G, Patey N, Cazajous G, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant. 2009;24:682–5.

    Article  PubMed  CAS  Google Scholar 

  75. Pelle G, Shweke N, Duong Van Huyen JP, et al. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am J Kidney Dis. 2011;57:756–9.

    Article  PubMed  CAS  Google Scholar 

  76. Hauglustaine D, Van Damme B, Vanrenterghem Y, Michielsen P. Recurrent hemolytic uremic syndrome during oral contraception. Clin Nephrol. 1981;15:148–53.

    PubMed  CAS  Google Scholar 

  77. Holdrinet RS, de Pauw BE, Haanen C. Hormonal dependent thrombotic thrombocytopenic purpura (TTP). Scand J Haematol. 1983;30:250–6.

    Article  PubMed  CAS  Google Scholar 

  78. Montes A, Powles TJ, O’Brien ME, Ashley SE, Luckit J, Treleaven J. A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Eur J Cancer. 1993;29A:1854–7.

    Article  PubMed  CAS  Google Scholar 

  79. Hauglustaine D, Vanrenterghem Y, Michielsen OP, van Damme B. Oestrogen containing oral contraceptives, decreased prostacyclin production, and haemolytic uraemic syndrome. Lancet. 1981;1:328–9.

    Article  PubMed  CAS  Google Scholar 

  80. Hachem RR, Yusen RD, Chakinala MM, Aloush AA, Patterson GA, Trulock EP. Thrombotic microangiopathy after lung transplantation. Transplantation. 2006;81:57–63.

    Article  PubMed  Google Scholar 

  81. Karthikeyan V, Parasuraman R, Shah V, Vera E, Venkat KK. Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant. 2003;3:1289–94.

    Article  PubMed  Google Scholar 

  82. Izzedine H, Sene D, Hadoux J, et al. Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment? Ann Oncol. 2011;22:487–90.

    Article  PubMed  CAS  Google Scholar 

  83. Francis KK, Kalyanam N, Terrell DR, Vesely SK, George JN. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases. Oncologist. 2007;12:11–9.

    Article  PubMed  Google Scholar 

  84. Elliott MA, Letendre L, Gastineau DA, Winters JL, Pruthi RK, Heit JA. Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Eur J Haematol. 2010;85:43–50.

    PubMed  CAS  Google Scholar 

  85. Fontana S, Gerritsen HE, Kremer Hovinga J, Furlan M, Lammle B. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br J Haematol. 2001;113:100–2.

    Article  PubMed  CAS  Google Scholar 

  86. Oberic L, Buffet M, Schwarzinger M, et al. Cancer awareness in atypical thrombotic microangiopathies. Oncologist. 2009;14:769–79.

    Article  PubMed  Google Scholar 

  87. Smith EP. Hematologic disorders after solid organ transplantation. Hematology Am Soc Hematol Educ Program. 2010;2010:281–6.

    Article  PubMed  Google Scholar 

  88. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676–87.

    Article  PubMed  CAS  Google Scholar 

  89. Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis. 2003;41:471–9.

    Article  PubMed  Google Scholar 

  90. Reynolds JC, Agodoa LY, Yuan CM, Abbott KC. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis. 2003;42:1058–68.

    Article  PubMed  Google Scholar 

  91. Shindoh J, Sugawara Y, Akamatsu N, et al. Thrombotic microangiopathy after living-donor liver transplantation. Am J Transplant. 2012;12:728–36.

    Article  PubMed  CAS  Google Scholar 

  92. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant. 1994;14:495–504.

    PubMed  CAS  Google Scholar 

  93. Paquette RL, Tran L, Landaw EM. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Bone Marrow Transplant. 1998;22:351–7.

    Article  PubMed  CAS  Google Scholar 

  94. van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood. 1999;93:3798–802.

    PubMed  Google Scholar 

  95. Cho BS, Yahng SA, Lee SE, et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010;90:918–26.

    Article  PubMed  CAS  Google Scholar 

  96. Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest. 1986;55:455–62.

    PubMed  CAS  Google Scholar 

  97. Lovric S, Kielstein JT, Kayser D, et al. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients—a case series. Nephrol Dial Transplant. 2011;26:3032–8.

    Article  PubMed  CAS  Google Scholar 

  98. Batts ED, Lazarus HM. Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant. 2007;40:709–19.

    Article  PubMed  CAS  Google Scholar 

  99. Swisher KK, Doan JT, Vesely SK, et al. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica. 2007;92:936–43.

    Article  PubMed  CAS  Google Scholar 

  100. Upshaw Jr JD. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med. 1978;298:1350–2.

    Article  PubMed  Google Scholar 

  101. Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol. 2001;14:437–54.

    Article  PubMed  CAS  Google Scholar 

  102. George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2003;10:339–44.

    Article  PubMed  Google Scholar 

  103. Bhatia M, Wong FL, Cao Y, et al. Pathophysiology of acute pancreatitis. Pancreatology. 2005;5:132–44.

    Article  PubMed  Google Scholar 

  104. Booth KK, Terrell DR, Vesely SK, George JN. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol. 2011;86:743–51.

    Article  PubMed  Google Scholar 

  105. Moore RD. Schistocytosis and a thrombotic microangiopathy-like syndrome in hospitalized HIV-infected patients. Am J Hematol. 1999;60:116–20.

    Article  PubMed  CAS  Google Scholar 

  106. Tamkus D, Jajeh A, Osafo D, Hadad L, Bhanot B, Yogore 3rd MG. Thrombotic microangiopathy syndrome as an AIDS-defining illness: the experience of J. Stroger Hospital of Cook County. Clin Adv Hematol Oncol. 2006;4:145–9.

    PubMed  Google Scholar 

  107. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium. 2000;7:223–42.

    PubMed  CAS  Google Scholar 

  108. del Arco A, Martinez MA, Pena JM, et al. Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus infection: demonstration of p24 antigen in endothelial cells. Clin Infect Dis. 1993;17:360–3.

    Article  PubMed  Google Scholar 

  109. Hofman FM, Wright AD, Dohadwala MM, Wong-Staal F, Walker SM. Exogenous tat protein activates human endothelial cells. Blood. 1993;82:2774–80.

    PubMed  CAS  Google Scholar 

  110. Park IW, Ullrich CK, Schoenberger E, Ganju RK, Groopman JE. HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J Immunol. 2001;167:2766–71.

    PubMed  CAS  Google Scholar 

  111. Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis. 2008;47:1209–15.

    Article  PubMed  Google Scholar 

  112. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005;3:1432–6.

    Article  PubMed  CAS  Google Scholar 

  113. Novitzky N, Thomson J, Abrahams L, du Toit C, McDonald A. Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy. Br J Haematol. 2005;128:373–9.

    Article  PubMed  Google Scholar 

  114. Malak S, Wolf M, Millot GA, et al. Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity. Scand J Immunol. 2008;68:337–44.

    Article  PubMed  CAS  Google Scholar 

  115. Gervasoni C, Ridolfo AL, Vaccarezza M, et al. Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis. 2002;35:1534–40.

    Article  PubMed  Google Scholar 

  116. Becker S, Fusco G, Fusco J, et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis. 2004;39 Suppl 5:S267–75.

    Article  PubMed  Google Scholar 

  117. Hart D, Sayer R, Miller R, et al. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura—favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol. 2011;153:515–9.

    Article  PubMed  CAS  Google Scholar 

  118. Nguyen L, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008. Transfusion. 2009;49:392–4.

    Article  PubMed  CAS  Google Scholar 

  119. Chang JC, Shipstone A, Llenado-Lee MA. Postoperative thrombotic thrombocytopenic purpura following cardiovascular surgeries. Am J Hematol. 1996;53:11–7.

    Article  PubMed  CAS  Google Scholar 

  120. Pavlovsky M, Weinstein R. Thrombotic thrombocytopenic purpura following coronary artery bypass graft surgery: prospective observations of an emerging syndrome. J Clin Apher. 1997;12:159–64.

    Article  PubMed  CAS  Google Scholar 

  121. Naqvi TA, Baumann MA, Chang JC. Post-operative thrombotic thrombocytopenic purpura: a review. Int J Clin Pract. 2004;58:169–72.

    Article  PubMed  CAS  Google Scholar 

  122. Saltzman DJ, Chang JC, Jimenez JC, et al. Postoperative thrombotic thrombocytopenic purpura after open heart operations. Ann Thorac Surg. 2010;89:119–23.

    Article  PubMed  Google Scholar 

  123. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The author of this chapter is grateful for the images kindly provided by Dr. Sanjeev Sethi, Mayo Clinic, Rochester.

Author information

Authors and Affiliations

  1. Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN, USA

    Qi Qian M.D.

Authors
  1. Qi Qian M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qi Qian M.D. .

Editor information

Editors and Affiliations

  1. Div. Nephrology & Hypertension, Mayo Clinic Dept. Internal Medicine, Rochester, Minnesota, USA

    Fernando C. Fervenza

  2. Renal Division, Brigham and Women's Hospital, Boston, Massachusetts, USA

    Julie Lin

  3. Mayo Clinic, Rochester, Minnesota, USA

    Sanjeev Sethi

  4. Renal Division, Brigham and Women's Hospital Harvard Medical School, Boston, Massachusetts, USA

    Ajay K. Singh

Additional information

Financial Disclosure: None

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Qian, Q. (2014). Thrombotic Microangiopathy Not Associated with the Classic/Idiopathic TTP-HUS. In: Fervenza, F., Lin, J., Sethi, S., Singh, A. (eds) Core Concepts in Parenchymal Kidney Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8166-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8166-9_16

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8165-2

  • Online ISBN: 978-1-4614-8166-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation